Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;384(6):543-53.
doi: 10.1007/s00210-011-0670-6. Epub 2011 Sep 8.

Agents increasing cyclic GMP amplify 5-HT4-elicited positive inotropic response in failing rat cardiac ventricle

Affiliations

Agents increasing cyclic GMP amplify 5-HT4-elicited positive inotropic response in failing rat cardiac ventricle

Faraz Afzal et al. Naunyn Schmiedebergs Arch Pharmacol. 2011 Dec.

Abstract

Activation of 5-HT(4) receptors in failing ventricles elicits a cAMP-dependent positive inotropic response which is mainly limited by the cGMP-inhibitable phosphodiesterase (PDE) 3. However, PDE4 plays an additional role which is demasked by PDE3 inhibition. The objective of this study was to evaluate the effect of cGMP generated by particulate and soluble guanylyl cyclase (GC) on the 5-HT(4)-mediated inotropic response. Extensive myocardial infarctions were induced by coronary artery ligation in Wistar rats, exhibiting heart failure 6 weeks after surgery. Contractility was measured in left ventricular preparations. Cyclic GMP was measured by EIA. In ventricular preparations, ANP or BNP displayed no impact on 5-HT(4)-mediated inotropic response. However, CNP increased the 5-HT(4)-mediated inotropic response as well as the β(1)-adrenoceptor (β(1)-AR)-mediated response to a similar extent as PDE3 inhibition by cilostamide. Pretreatment with cilostamide eliminated the effect of CNP. Inhibition of nitric oxide (NO) synthase and soluble GC by L-NAME and ODQ, respectively, attenuated the 5-HT(4)-mediated inotropic response, whereas the NO donor Sin-1 increased this response. The effects were absent during PDE3 inhibition, suggesting cGMP-dependent inhibition of PDE3. However, in contrast to the effects on the 5-HT(4) response, Sin-1 inhibited whereas L-NAME and ODQ enhanced the β(1)-AR-mediated inotropic response. cGMP generated both by particulate (NPR-B) and soluble GC increases the 5-HT(4)-mediated inotropic response in failing hearts, probably through inhibition of PDE3. β(1)-AR and 5-HT(4) receptor signalling are subject to opposite regulatory control by cGMP generated by soluble GC in failing hearts. Thus, cGMP from different sources is functionally compartmented, giving differential regulation of different G(s)-coupled receptors.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Concentration–response curves of inotropic responses to 5-HT4 receptor stimulation in the absence (control) or presence of natriuretic peptides; 1 μM ANP, 1 μM BNP or 300 nM CNP. Natriuretic peptides were added 20 min before 5-HT. Ordinate: inotropic response expressed as increase in (dF/dt)max in percent above basal. Vertical bars represent SEM of maximal inotropic responses. Abscissa: concentration of the agonist. Horizontal bars represent SEM of –logEC50. Double asterisks: p < 0.01 vs. control
Fig. 2
Fig. 2
a Concentration–response curves of inotropic responses to 5-HT4 receptor stimulation in papillary muscles in the absence (control) or presence of 300 nM CNP or in combination with PDE inhibitors (Cil, 1 μM cilostamide; Rol, 10 μM rolipram). b Concentration–response curves of inotropic responses (normalized) to β1-adrenoceptor stimulation by (−)-noradrenaline (50 nM ICI118551 present) in absence (control) or presence of CNP or in combination with PDE inhibitors (Cil, 1 μM cilostamide; Rol, 10 μM rolipram) in left ventricular strips. CNP and PDE inhibitors were added 20 and 45 min before the agonist, respectively. Ordinate: inotropic response expressed as increase in (dF/dt)max in percent above basal (a) or as percent of maximum (normalized) (b). Vertical bars represent SEM of maximal inotropic responses. Abscissa: concentration of the agonist. Horizontal bars represent SEM of –logEC50. Double asterisks: p < 0.01 CNP vs. control (for maximal response in a, and –logEC50 in b). Single crosses: p < 0.01 CNP/Rol vs. CNP (for maximal response in a, and –logEC50 in b). Double crosses: p < 0.01 –logEC50 CNP/Rol vs. CNP
Fig. 3
Fig. 3
Cyclic GMP levels in left ventricular strips in absence (control) or presence of 100 μM l-NAME (NOS inhibitor), 10 μM ODQ (sGC inhibitor) or 300 μM Sin-1 (NO donor). l-NAME and ODQ were added 45 min before and Sin-1 20 min before the ventricular strips were snap-frozen. Number of experiments “ninside the bars; mean±SEM. Asterisk: p < 0.05 vs. control. Number sign: p = 0.16 vs. control (after Bonferroni correction)
Fig. 4
Fig. 4
a, b Concentration–response curves of inotropic responses to 5-HT4 receptor stimulation in the absence (control) and presence of 100 μM l-NAME (NOS inhibitor), 10 μM ODQ (sGC inhibitor), 300 μM Sin-1 (NO donor) or in combination with PDE inhibitors (Cil, 1 μM cilostamide; Rol, 10 μM rolipram) in papillary muscles. All the inhibitors were added 45 min before 5-HT, whereas Sin-1 was added 20 min before 5-HT. Ordinate: inotropic response expressed as increase in (dF/dt)max in percent above basal. Vertical bars represent SEM of inotropic response. Abscissa: concentration of the agonist. Horizontal bars represent SEM of –logEC50. Asterisk: p < 0.05 vs. control. Number sign: p = 0.08 vs. control (after Bonferroni correction)
Fig. 5
Fig. 5
Concentration–response curves of inotropic responses (normalized) to β1-adrenoceptor stimulation by (−)-noradrenaline (50 nM ICI118551 present) in absence (control) or presence of 100 μM l-NAME (NOS inhibitor), 10 μM ODQ (sGC inhibitor) or 300 μM Sin-1 (NO donor) in left ventricular strips. l-NAME and ODQ were added 45 min before and Sin-1 20 min before the (−)-noradrenaline. Ordinate: inotropic response expressed as increase in (dF/dt)max in percent of maximum (normalized). Abscissa: concentration of the agonist. Horizontal bars represent SEM of –logEC50. Double asterisks: p < 0.01 vs. control
Fig. 6
Fig. 6
Illustration of the proposed functional compartmentation of 5-HT4 receptor, β1-adrenoceptor and cyclic nucleotides in cardiac myocytes. The inotropic response to 5-HT4 receptor and β1-adrenoceptor stimulation is mediated by cAMP and regulated by PDE3. 1: cGMP generated by NPR-B inhibits PDE3 and increases the 5-HT4 receptor- and β1-adrenoceptor-mediated inotropic response. 2: cGMP generated by NPR-A has no access to the PDE3 regulating inotropic response. 3: A pool of cGMP generated by sGC increases the 5-HT4-mediated inotropic response by inhibiting PDE3. 4: A pool of cGMP generated by sGC has no access to the PDE3 regulating the β1-adrenoceptor-mediated inotropic response, but inhibits it by some other mechanism, possibly through PKG

Similar articles

Cited by

References

    1. Afzal F, Andressen KW, Mørk HK, Aronsen JM, Sjaastad I, Dahl CP, Skomedal T, Levy FO, Osnes JB, Qvigstad E. 5-HT4-elicited positive inotropic response is mediated by cAMP and regulated by PDE3 in failing rat and human cardiac ventricles. Br J Pharmacol. 2008;155:1005–1014. doi: 10.1038/bjp.2008.339. - DOI - PMC - PubMed
    1. Afzal F, Aronsen JM, Moltzau LR, Sjaastad I, Levy FO, Skomedal T, Osnes JB, Qvigstad E. Differential regulation of β2-adrenoceptor-mediated inotropic and lusitropic response by PDE3 and PDE4 in failing and non-failing rat cardiac ventricle. Br J Pharmacol. 2011;162:54–71. doi: 10.1111/j.1476-5381.2010.00890.x. - DOI - PMC - PubMed
    1. Bendall JK, Damy T, Ratajczak P, Loyer X, Monceau V, Marty I, Milliez P, Robidel E, Marotte F, Samuel JL, Heymes C. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in β-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation. 2004;110:2368–2375. doi: 10.1161/01.CIR.0000145160.04084.AC. - DOI - PubMed
    1. Birkeland JA, Sjaastad I, Brattelid T, Qvigstad E, Moberg ER, Krobert KA, Bjørnerheim R, Skomedal T, Sejersted OM, Osnes JB, Levy FO. Effects of treatment with a 5-HT4 receptor antagonist in heart failure. Br J Pharmacol. 2007;150:143–152. doi: 10.1038/sj.bjp.0706966. - DOI - PMC - PubMed
    1. Brattelid T, Qvigstad E, Lynham JA, Molenaar P, Aass H, Geiran O, Skomedal T, Osnes J-B, Levy FO, Kaumann AJ. Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure. Naunyn-Schmied Arch Pharmacol. 2004;370:157–166. doi: 10.1007/s00210-004-0963-0. - DOI - PubMed

Publication types

MeSH terms

Substances